Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The inhibitor of the redox activity of APE1/REF-1, APX2009, reduces the malignant phenotype of breast cancer cells.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas - 1 Jan 2024

Siqueira P B, Rodrigues M M S, Amorim Ĺ S S de, Rodrigues J A, Oliveira M S, Fonseca A S, Pires B R B, Mencalha A L

Abstract excerpt

Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/REF-1) is a multifunctional protein acting on cellular signaling pathways, including DNA repair and redox activities. APE1/REF-1 has emerged as a target for cancer therapy, and its role in breast cancer models would reveal new strategies for cancer therapy. APX2009 is a specific APE1/REF-1 redox inhibitor whose anticancer properties have not been described...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Cell Movement

Share to Cell Proliferation

Share to DNA-(Apurinic or Apyrimidinic Site) Lyase

Share to MCF-7 Cells

Share to Oxidation-Reduction

Source

Open in PubMed Open full text

Identifiers

PMID: 38808886
DOI: 10.1590/1414-431X2024e13250
PMCID: PMC11136485

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The inhibitor of the redox activity of APE1/REF-1, APX2009, reduces the malignant phenotype of breast cancer cells.PMID 38808886Read ↗

Anticancer clinical utility of the apurinic/apyrimidinic endonuclease/redox factor-1 (APE/Ref-1).Semantic proximity Read ↗

Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinicSemantic proximity Read ↗

The APE1 redox inhibitor E3330 reduces collective cell migration of human breast cancer cells and decreases chemoinvasion and colony formation when combined with docetaxelSemantic proximity Read ↗

New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer typesSemantic proximity Read ↗

APE1/Ref-1 Role in Inflammation and Immune ResponseSemantic proximity Read ↗

The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive targetSemantic proximity Read ↗

Inhibiting the Redox Function of APE1 Suppresses Cervical Cancer Metastasis via Disengagement of ZEB1 from E-cadherin in EMTSemantic proximity Read ↗

Revisiting Two Decades of Research Focused on Targeting APE1 for Cancer Therapy: The Pros and ConsSemantic proximity Read ↗

An APE1 inhibitor reveals critical roles of the redox function of APE1 in KSHV replication and pathogenic phenotypes.Semantic proximity Read ↗

A review on protein–protein interaction network of APE1/Ref‐1 and its associated biological functionsSemantic proximity Read ↗

EGR1 Promotes Erastin-induced Ferroptosis Through Activating Nrf2-HMOX1 Signaling Pathway in Breast Cancer CellsSemantic proximity Read ↗

APE 1/Ref‐1 knockdown in pancreatic ductal adenocarcinoma – characterizing gene expression changes and identifying novel pathways using single‐cell RNA sequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.